Powered by sales that averaged more than $25 million a day for brand-new hep C drug Sovaldi, Gilead Sciences beat all expectations, with quarterly sales that nearly doubled and profits that tripled in the first quarter.
written on 22.04.2014
Gilead's Sovaldi turns in outsize Q1 sales
